Skip to main content
Log in

Elimination of liposomal amphotericin by hemodiafiltration

  • Correspondence
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Tollemar J, Andersson S, Ringden O, Tygen G (1992) A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients. Mycoses 35(9–10):215–220

    Google Scholar 

  2. Meunier F, Prentice HG, Ringden O (1991) Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 28 [Suppl B]:83–91

    Google Scholar 

  3. Jankneft R, Siem de Marie, Bakker-Woudenberg IAJM, Crommelin DJA (1992) Liposomal and lipid formulations of amphotericin B. Clin Pharmacokinet 23:279–291

    Google Scholar 

  4. Golper TA (1991) Drug removal during continuous hemofiltration or haemodialysis. In: Siebet HG, Mann H, Stummvoll HK (eds) Continuous hemofiltration. Contrib Nephrol, Karger, Basel, 93:110–116

    Google Scholar 

  5. Humphreys H, Oliver DA, Winter R, Warnock DA (1994) Liposomal amphotericin B and continuous venous-venous haemofiltration. J Antimicrob Chemother 33:1071

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tomlin, M., Priestley, G.S. Elimination of liposomal amphotericin by hemodiafiltration. Intensive Care Med 21, 699–700 (1995). https://doi.org/10.1007/BF01711556

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01711556

Keywords

Navigation